Filtered By:
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 60 results found since Jan 2013.
E-258 Endovascular approach to drug delivery to the brain
ConclusionsCPA delivery of AAV9 resulted in increased transduction of the parietal and cingulate cortex, comparable to that observed with CM injections. These results provide preliminary evidence that CPA infusion of gene therapy, and potentially other therapies such as antisense oligonucleotides or siRNA medications, is safe and provides widespread distribution throughout the brain.Abstract E-258 Figure 1Disclosures A. Malek: 4; C; CereVasc. H. Benatti: None. V. Anagnostakou: None. E. Hall: None. C. Heilman: 4; C; CereVasc. B. Beneduce: 4; C; CereVasc. A. Leporati: None. R. King: None. M. Gounis: 1; C; Research support fr...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Malek, A., Benatti, H., Anagnostakou, V., Hall, E., Heilman, C., Beneduce, B., Leporati, A., King, R., Gounis, M., Gray-Edwards, H. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research
The Upregulation of GSTO2 is Associated with Colon Cancer Progression and a Poor Prognosis
J Oncol. 2023 Jan 11;2023:4931650. doi: 10.1155/2023/4931650. eCollection 2023.ABSTRACTColorectal cancer is the second-leading cause of cancer-related mortality in the United States. Glutathione S-transferase can affect the development of cancer. Glutathione S-transferase omega 2, a member of the GST family, plays an important role in many tumors. However, the role of Glutathione S-transferase omega 2 in the development of colon cancer remains unclear. Herein, our study aimed to investigate the exact role of Glutathione S-transferase omega 2 in colon cancer. We used RNA sequencing data from The Cancer Genome Atlas and the ...
Source: Journal of Oncology - January 23, 2023 Category: Cancer & Oncology Authors: Xingyu Peng Jinfeng Zhu Sicheng Liu Zitao Liu Chen Luo Xun Wu Zhonglin Yu Zhengming Zhu Source Type: research
Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic
On December 22, 2021, the United States FDA approved inclisiran, an siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and statin therapy for low-density lipoprotein cholesterol (LDL-C) reduction in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).1 Inclisiran has demonstrated ∼50% time-averaged reduction in LDL-C and offers potential in promoting patient adherence as a twice-yearly long-acting injectable.
Source: Journal of Clinical Lipidology - October 31, 2022 Category: Lipidology Authors: Tommy T. Chiou, Kimberly Tomasi, Pam R. Taub, Michael J. Wilkinson Tags: Brief Communication Source Type: research
Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research
Cancers, Vol. 14, Pages 3162: Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo
In this study, siRNA was designed for the targeted knockdown of 15-bp deletion-type BRAF mRNA. This siRNA repressed the phosphorylation of extracellular-signal-regulated kinase proteins downstream of BRAF and suppressed cell growth in vitro and in vivo. Furthermore, siRNAs with 2&prime;-O-methyl modifications at positions 2&ndash;5 reduce the seed-dependent off-target effects, as confirmed by reporter and microarray analyses. Thus, such siRNA is a promising candidate therapy for 15-bp deletion-type BRAF-induced tumorigenesis.
Source: Cancers - June 28, 2022 Category: Cancer & Oncology Authors: Jiaxuan Song Yoshiaki Kobayashi Yoshimasa Asano Atsushi Sato Hiroaki Taniguchi Kumiko Ui-Tei Tags: Article Source Type: research
